Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc. scores highest on Earnings (77) and lowest on Price (12). Its PosiPenta is 52.87 out of 100, around the middle of similar companies.
On the Penta Grid this week, Gyre Therapeutics, Inc. is Grid #238 of 837 in the Healthcare sector in United States, and Grid #1,537 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Gyre Therapeutics, Inc. | 52.87 | 12 | 77 | 57 | 68 | 51 |
| Olema Pharmaceuticals, Inc. | 33.98 | 35 | 24 | 13 | 62 | 36 |
| Zevra Therapeutics, Inc. | 63.08 | 63 | 58 | 62 | 86 | 46 |
| CorMedix Inc. | 58.56 | 80 | 47 | 50 | 67 | 49 |
| Climb Bio, Inc. | 43.67 | 26 | 35 | 61 | 70 | 27 |
| Pacific Biosciences of California, Inc. | 28.28 | 0 | 44 | 52 | 2 | 44 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -24.32 |
| P/B ratio | 5.97 |
EEarnings
| Trailing EPS | ₹-23.68 |
| Forward EPS | ₹5.68 |
NNitro
| Price | 575.87 |
| 52-week high | 865.69 |
| 52-week low | 515.25 |
| Fall from 52-week high | 33.5% |
TTorque
| Return on equity (ROE) | -17.44% |
| Debt-to-equity | 0.02 |
AAnchor
| Beta (price swings) | 4.74 |
| Market cap | ₹6,106 Cr |
| Insider holding | 74.40% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Gyre Therapeutics, Inc.'s PosiPenta score?
Gyre Therapeutics, Inc.'s PosiPenta is 52.87 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Gyre Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Gyre Therapeutics, Inc. is Grid #238 of 837 in the Healthcare sector in United States, and Grid #1,537 of 4,000 in United States.
Which PosiPenta pillar is strongest for Gyre Therapeutics, Inc.?
Earnings (growth), with a score of 77 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Gyre Therapeutics, Inc.?
Price (valuation), with a score of 12 out of 100: much weaker than most similar companies.
Has Gyre Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.59 points, from 50.28 to 52.87.
PositoAI is for research and education only and is not investment advice.